ferrous citrate
Ferrous citrate, also known as iron(II) citrate or iron(2+) citrate, describes coordination complexes containing citrate anions with Fe2+ formed in aqueous solution. Although a number of complexes are possible (or even likely), only one complex has been crystallized. That complex is the coordination polymer with the formula [Fe(H2O)6]2+{[Fe(C6H5O7)(H2O)]−}2.2H2O, where C6H5O73- is HOC(CH2CO2−)2(CO2−, i.e., the triple conjugate base of citric acid wherein the three carboxylic acid groups are ionized. Ferrous citrates are all paramagnetic, reflecting the weak crystal field of the carboxylate ligands. — Wikipedia
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Sep 6, 2019 (NCT04020653)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- IronSupplementation
Iron supplementation
Chemistry & pharmacology
- Mol. weight
- 545.73 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIron(II) citrate ↗
- ChEMBLCHEMBL2110914 ↗
Also known as
- fe(ii) citrate
- ferrous citrate
- ferrous citrate
- ferrous citrate
- monoferrous acid citrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027670 | Phase 2 | Feb 1, 2021 | Emerald Clinical Inc., SBI Pharmaceuticals Co, Ltd., University of Oxford |
| NCT04020653 | Phase 2 | Sep 6, 2019 | Neopharma, Parexel |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emerald Clinical Inc. | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Neopharma | For profit | 1 | 1 | 1 | 2019 |
| Parexel | For profit | 1 | 0 | 1 | 2019 |
| SBI Pharmaceuticals Co, Ltd. | For profit | 1 | 0 | 1 | 2021 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2021 |